AsiaTIDES: Oligonucleotide & Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

February 24-26, 2020
The Westin Miyako Kyoto,
Kyoto, Japan

THE ONLY EVENT IN ASIA BRINGING TOGETHER SCIENCE, TECHNOLOGIES AND PARTNERS TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE MOLECULES TO MARKET

Get the latest event updates

Sign up to get the latest event updates and information.

AsiaTIDES Provides Access To the Science, Technologies and Partners You Need to Grow Your Business

Accelerate Your Product to Market

Hear case studies, best practices and lessons learned from global oligonucleotide and peptide developers currently in phase 2/3 clinical trials. Ensure product approval by hearing regulatory guidance and roadmaps to successful IND/IMPD submissions from industry leaders.

View the 2019 Agenda
Evaluate New Technologies and Services

Improve your process development, analytical and manufacturing efforts by meeting with 20+ global technology leaders in the exhibit hall. The exhibit hall also features peer-submitted posters that contain new and unpublished research from global scientists working across all phases of oligonucleotide and peptide development.

See Who Exhibited at AsiaTIDES 2019
Meet Your Next Partner at AsiaTIDES

Connect with 250+ oligonucleotide and peptide leaders across Asia, Europe and North America during networking lunches, dinners and cocktail receptions.

Check out the 2019 Networking Opportunities

CONNECT WITH KEY BUYERS AT AsiaTIDES 2020


Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.  

 Contact Michael Dunnet: MDunnet@knect365lifesciences.com | +1 (857) 504-6732

CROSS-FERTILIZE IDEAS AND BEST PRACTICES WITH RESEARCHERS FROM DIFFERENT DISCIPLINES

AsiaTIDES offers separate tracks covering the latest oligonucleotide and peptide development strategies from discovery, nonclinical, clinical and CMC to late-stage development and commercialization. 

2019 Oligonucleotide Track Highlights
  • Learn about advances in mRNA therapeutic development and CMC
  • Find new approaches to optimize oligonucleotide properties
  • Increase efficiency in oligonucleotide CMC and manufacturing
  • Overcome the delivery challenge by learning about new delivery technologies
  • Hear data from preclinical and clinical case studies with lessons learned
  • Pre-Conference Workshop: Accelerating Oligonucleotides to IND and Beyond
2019 Peptide Track Highlights
  • Implement new approaches for peptide discovery and drug target identification
  • Discover the latest in peptide synthesis technologies and methods
  • Find new approaches to optimize peptide properties
  • Increase efficiency in peptide CMC and manufacturing
  • Hear data from preclinical and clinical case studies with lessons learned
  • Pre-Conference Workshop: Accelerating Peptides to IND: Moving to the Clinic, CMC and Beyond
What was new for 2019
  • mRNA therapeutics session featuring Moderna Therapeutics, BioNTech and CureVac
  • 1st Time Presenting Companies: WAVE, Stoke, CuroNZ, NapaJen, FunPep and more!
  • Expanded regulatory session for both peptides and oligonucleotides
  • More exhibitors and poster presentations than ever before

Meet the AsiaTIDES 2019 Scientific Advisory Board

Thank you for bringing in top global scientists oligonucleotide and peptide field to speak on the AsiaTIDES 2019 agenda. 

  • Hiroaki Suga, Ph.D., Professor of Chemistry, School of Science, University of Tokyo, Japan 
  • Osamu Sato, Ph.D., General Manager, Sakigake-Projects; DS-5141 and DS-1647 and Senior Executive Advisor for Head of R&D, Daiichi Sankyo Co., Ltd., Japan
  • Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals 
  • James Thompson, Ph.D., Head of CMC Project Management, Moderna Therapeutics, Inc.
  • Daisuke Takahashi, Ph.D., Senior Principal Researcher, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., Japan
  • Hideaki Sato, President and CEO, Luxna Biotech, Japan
  • Robert Hagopian, Director Business Development, PolyPeptide Laboratories, USA
  • Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University and CEO & Founder, OliX Pharmaceuticals, Korea
  • Shawn Lee, Ph.D., President and CEO, CPC Scientific, USA and China 
  • Patrick Lu, Ph.D., Founder, President and CEO, Sirnaomics, Inc., USA 
  • Michael McGinley, Global Technical Manager, Phenomenex, USA
  • Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest, USA
  • El Djouhar Rekaï, Head of Peptide Products Operation, PolyPeptide Group, Belgium
  • Susan Srivatsa, Ph.D., President, ElixinPharma, USA 
  • Dmitry Samarsky, Ph.D., Chief Technology Officer, Sirnaomics, USA
  • Mimoun Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland